Opthea Secures Up To US$170 Mln In Financing For OPT-302 In Wet AMD

Opthea Limited (OPT, OPT.AX) said that it has secured up to US$170 million in non-dilutive financing to advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. The financing consists of a US$120 million commitment and has an option to increase funding by a further US$50 million.

If OPT-302 is approved in a major market, Carlyle and Abingworth will be eligible to receive fixed success payments and variable success payments of 7% on annual net sales, which terminate after reaching four times the funded amount.

Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.

OPT-302 is a first-in-class intravitreally administered biologic "trap" inhibitor of vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) currently being investigated in two concurrent Phase 3 pivotal registrational trials that will each enroll ~990 treatment naïve patients, in combination with two approved anti-VEGF-A treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial). OPT-302 has the potential to be positioned as complementary and agnostic with any combined anti-VEGF-A therapy for the treatment of wet AMD.

In addition, Opthea has received commitments for US$90 million through a private institutional equity placement for new shares and launched an A$5 million Share Purchase Plan.

Opthea is expected to be fully funded through pivotal Phase 3 topline data and pre-commercial activities and retains full worldwide commercial rights to OPT-302.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Retailers Dollar General Corp. (DG) and Big Lots, Inc. (BIG) reported Thursday results for the third quarter, with profit at Dollar General increasing from last year, while Big Lots reported a sharply wider loss than last year. The bottom line at both the retailers missed analysts' estimates. The U.S. Food and Drug Administration said it has granted approval for Ferring Pharmaceuticals Inc.'s fecal microbiota product Rebyota. The approval is for the prevention of recurrence of Clostridioides difficile infection or CDI in individuals 18 years of age and older. Rebyota will be used after an individual has completed antibiotic treatment for recurrent CDI. Salt Lake City, Utah-based Rocky Mountain Pies, LLC is recalling Red Button Vintage Creamery French Silk Pie citing possible presence of undeclared almonds, a known allergen, the U.S. Food and Drug Administration said. The recall involves 31.88 oz French Silk Pie with the lot code beginning with 2 266. Only UPC code 0 41172 81290 9 is involved in the recall.
Follow RTT